Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents

IMPORTANCE: Greater than 20% of cases and 0.4% of deaths from COVID-19 occur in children. Following demonstration of the safety and efficacy of the adjuvanted, recombinant spike protein vaccine NVX-CoV2373 in adults, the PREVENT-19 trial immediately expanded to adolescents. OBJECTIVE: To evaluate th...

Descripción completa

Detalles Bibliográficos
Autores principales: Áñez, Germán, Dunkle, Lisa M., Gay, Cynthia L., Kotloff, Karen L., Adelglass, Jeffrey M., Essink, Brandon, Campbell, James D., Cloney-Clark, Shane, Zhu, Mingzhu, Plested, Joyce S., Roychoudhury, Pavitra, Greninger, Alexander L., Patel, Nita, McGarry, Alice, Woo, Wayne, Iksung, Cho, Glenn, Gregory M., Dubovsky, Filip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10536880/
https://www.ncbi.nlm.nih.gov/pubmed/37099299
http://dx.doi.org/10.1001/jamanetworkopen.2023.9135

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10536880/
https://www.ncbi.nlm.nih.gov/pubmed/37099299
http://dx.doi.org/10.1001/jamanetworkopen.2023.9135

Ejemplares similares